CROOZ
16.5.2023 05:01:27 CEST | Business Wire | Press release
CROOZ, Inc. (listed on the Tokyo Stock Exchange Standard Market: 2138; head office: Shibuya-ku, Tokyo; the President and CEO: Koji Obuchi; hereinafter "CROOZ") announced that it has officially launched PROJECT XENO, an NFT game developed by the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005017/en/
XENO_TOP (Graphic: Business Wire)
About PROJECT XENO
PROJECT XENO is a blockchain game operated by EPOCH FACTORY and developed by CROOZ, a listed Japanese company. The full-scale tactical battle NFT game combines GameFi, e-Sports, and Fun. PROJECT XENO is available globally and can be played on smartphones and PCs.
PROJECT XENO has the following features.
Feature (1) Collaboration with celebrities such as Floyd Mayweather JR
The game has appointed some ambassadors to reach users around the world; popular YouTuber Hikaru as an ambassador in Japan, along with eight-division boxing world champion Manny Pacquiao and Fumiya, "the most famous Japanese in the Philippines," as ambassadors in Southeast Asia. In addition, NFTs collaborated with former five-division boxing world champion Floyd Mayweather Jr. and others are also available.
Feature (2) Developed by a listed Japanese company
PROJECT XENO is developed and operated by a listed company that has released many hit smartphone games in the Japanese market and is able to provide high-quality games and stable operations.
Feature (3) “Web 2.5” specifications that also enable users without NFT to play
PROJECT XENO is a free-to-play game, meaning that it can still be played by users who do not own NFT. Furthermore, the game supports in-game purchases, allowing users to play the game in exactly the same way as NFT holders. The only difference with NFT holders is the presence or absence of the Earn feature. There are no discrepancies in character strength, etc., allowing PROJECT XENO to be played like any other social game. If social games are Web 2.0 and GameFi games are Web 3.0, then PROJECT XENO can be considered a Web 2.5 game.
About GXE tokens
GXE is a token distributed on PROJECT XENO. GXE is listed on MEXC Global, LBank, BKEX, Bittrex Global, and Gate.io. On May 16, 2023 (Japan time), it was also listed on BITPoint, a crypto asset exchange of the SBI Group based in Tokyo, Japan. BITPoint has been approved as a crypto asset exchange operator by the Japanese Financial Services Agency.
The latest information on PROJECT XENO
For more information on PROJECT XENO, visit the website.
Up-to-date information is also available on Twitter.
- PROJECT XENO: http://project-xeno.com/
- PROJECT XENO Official Twitter: https://twitter.com/PROJECTXENO_GLB
About CROOZ, Inc.
With the fashion shopping site "SHOPLIST.com by CROOZ" at its core, CROOZ, Inc. develops a wide range of Internet services in the entertainment domain, including shopping and games, always in step with the changing times.
https://crooz.co.jp
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom